| Name | Title | Contact Details |
|---|
Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.
ICON Clinical Research is a North Wales, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Citizens Rx provides pharmacy benefit management services to public and private companies and offers health plans in the United States.
06795 Pfizer Inc. is an American multinational pharmaceutical corporation headquartered in New York City.
CSI TESTING Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.